Roche Holding AG is considering options for its diabetes-care business including a sale, Bloomberg reported, citing people familiar with the matter.
The alternatives for the unit could include a partial sale or spinoff and the sale could fetch as much as $5 billion, Bloomberg also reported.
The Swiss drugmaker had said last year that it has no plans to sells its diabetes testing business.
Johnson & Johnson said last week that it is looking to divest its diabetes division, while Bayer AG sold its diabetes business to KKR and Panasonic in 2015, for $1.1 billion.
Roche was not immediately available for comment outside regular business hours.
By Parikshit Mishra
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
